In Brief: Selfcare, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Acquires diabetes care product supplier Can-Am Care for approximately $27 mil., including $13.6 mil. in cash, a $2 mil. note and about 1.1 mil. shares of Selfcare common stock. Can-Am, which markets insulin syringes, blood lancets, glucose tablets and specialty skin creams to pharmacies nationwide, generated approximately $25 mil. in revenues in fiscal 1997. Selfcare, which makes health maintenance and home self-test diagnostic products for the diabetes, women's health and nutritional supplement markets, calls the acquisition "an excellent fit with the rest of Selfcare's business" and anticipates "good opportunities to increase our total shelf space in pharmacies where our products are sold." The acquisition is expected to be accretive to earnings...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.